Detection of circulating tumor cells and its application in breast cancer

doi:10.3877/cma.j.issn.1674-0793.2023.03.015

Abstract

Abstract:

Circulating tumor cells (CTC) are cells that fall off from primary tumors and circulate in the blood, and their metastasis and formation of a secondary tumor are closely associated with cancer-related death. In the last decade, many detection methods based on biological and physical differences in CTC have been developed. Recent studies indicate that CTC have the potential to predict prognosis in both primary and metastatic settings, and CTC may be one of the key indicators to predicting survival and therapeutic monitoring in breast cancer, and their characterization may be novel targets for biological therapies.

Key words: Circulating tumor cells, Detection method, Breast neoplasms, Prognosis

Xueyuan Feng, Mengmeng Han, Ning Ma. Detection of circulating tumor cells and its application in breast cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 231-236.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.03.015

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I03/231

References 35

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志, 2020, 42(10): 781-797.
[3]	Smit DJ, Pantel K, Jücker M. Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy[J]. Biochem Pharmac, 2021, 188: 114589.
[4]	Chelakkot C, Yang H, Shin YK. Relevance of circulating tumor cells as predictive markers for cancer incidence and relapse[J]. Pharmaceuticals, 2022, 15(1): 75.
[5]	Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J]. Clin Cancer Rese, 2004, 10(20): 6897-6904.
[6]	Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis[J]. J Clin Pathol, 2011, 64(5): 415-420.
[7]	Debnath P, Huirem RS, Dutta P, et al. Epithelial–mesenchymal transition and its transcription factors[J]. Biosci Rep, 2022, 42(1): BSR20211754.
[8]	Buyuk B, Jin S, Ye K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis[J]. Cell Mol Bioengineer, 2021, 15(1): 1-13.
[9]	Topa J, Grešner P, Żaczek A J, et al. Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?[J]. Cell Mol Life Sci, 2022, 79(2): 81.
[10]	Mendelaar PAJ, Kraan J, Van M, et al. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients[J]. Mol Oncol, 2021, 15(1): 116-125.
[11]	Rahmati M, Chen X. Separation of circulating tumor cells from blood using dielectrophoretic DLD manipulation[J]. Biomed Microdevices, 2021, 23(4): 49.
[12]	Farasat M, Chavoshi SM, Bakhshi A, et al. A dielectrophoresis-based microfluidic chip for trapping circulating tumor cells using a porous membrane[J]. J Micromechan Microengineer, 2021, 32(1): 015008.
[13]	Kalyan S, Torabi C, Khoo H, et al. Inertial microfluidics enabling clinical research[J]. Micromachines, 2021, 12(3): 257.
[14]	Soler A, Cayrefourcq L, Mazel M, et al. EpCAM-independent enrichment and detection of viable circulating tumor cells using the EPISPOT assay[M]//Circulating Tumor Cells. Humana Press, New York, NY, 2017: 263-276.
[15]	Park HS, Han HJ, Lee S, et al. Detection of circulating tumor cells in breast cancer patients using cytokeratin-19 real-time RT-PCR[J]. Yonsei Med J, 2017, 58(1): 19-26.
[16]	Descamps L, Le Roy D, Deman AL. Microfluidic-based technologies for CTC isolation: A review of 10 years of intense efforts towards liquid biopsy[J]. Int J Mol Sci, 2022, 23(4): 1981.
[17]	Farshchi F, Hasanzadeh M. Microfluidic biosensing of circulating tumor cells (CTCs): recent progress and challenges in efficient diagnosis of cancer[J]. Biomed Pharmacother, 2021, 134: 111153.
[18]	Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: An independent review[J]. Br J Cancer, 2013, 108(11): 2205-2240.
[19]	Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk[J]. JAMA, 2012, 307(13): 1394-1404.
[20]	Gao Y, Fan WH, Duan C, et al. Enhancing the screening efficiency of breast cancer by combining conventional medical imaging examinations with circulating tumor cells[J]. Front Oncol 2021, 11: 643003.
[21]	Janni WJ, Rack B, Terstappen LW, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancerJ]. Clin Cancer Res, 2016, 22(10): 2583-2593.
[22]	Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4): 406-414.
[23]	龚嘉, 徐峰, 周美容, 等.循环肿瘤细胞与早期乳腺癌临床病理特征的相关性[J]. 中南大学学报(医学版), 2019, 44(9): 1016-1022.
[24]	Zhou M, Jiang L, Fan Y, et al. Correlation between circulating tumor cells and different molecular biological characteristics in breast cancer patients[J]. Gland Surg, 2022, 11(2): 466-471.
[25]	李蕾, 刘毅, 张少华, 等. 循环肿瘤细胞检测在不同阶段不同类型乳腺癌中的应用及意义[J]. 中华医学杂志, 2014, 100(36): 2812-2815.
[26]	Sanches SM, Braun AC, Calsavara VF, et al. Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases[J]. Clinics, 2021, 76: e2971.
[27]	Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells[J]. Breast Cancer Res, 2009, 11(4): 1-9.
[28]	Bouris P, Skandalis SS, Piperigkou Z, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells[J]. Matrix Biol, 2015, 43: 42-60.
[29]	Müller V, Banys-Paluchowski M, Friedl TWP, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program[J]. ESMO Open, 2021, 6(6): 100299.
[30]	Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19 mRNA-positive circulating tumor cells: results of a randomized phase Ⅱ study[J]. Ann Oncol, 2012, 23(7): 1744-1750.
[31]	Schramm A, Friedl TWP, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program[J]. Arch Gynecol Obstet, 2016, 293(2): 271-281.
[32]	Shliakhtunou YA. CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study[J]. Breast Cancer Res Treat, 2021, 186(2): 439-451.
[33]	Yan WT, Cui X, Chen Q, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: A meta-analysis[J]. Sci Rep, 2017, 7(1): 1-12.
[34]	Duma MN. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer[J]. Strahlenther Onkol, 2018, 194(11): 1069-1071.
[35]	Wang J, Wang X, Chen R, et al. Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer[J]. Int J Clin Oncol, 2022, 27(5): 889-898.

Please choose a citation manager

Content to export